about
Reverse the Resistance to PARP Inhibitors.Endostatin Sensitizes p53-Deficient Non-Small Cell Lung Cancer to Genotoxic Chemotherapy by Targeting DNA-PKcs.E167K polymorphism of TM6SF2 gene affects cell cycle of hepatocellular carcinoma cell HEPA 1-6.Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician.Advancing Immunotherapy in Metastatic Breast Cancer.DNA Damage and Repair Biomarkers of Immunotherapy Response.Targeting DNA repair and replication stress in the treatment of ovarian cancer.The DNA damage response pathway in normal hematopoiesis and malignancies.Synthetic lethal short hairpin RNA screening reveals that ring finger protein 183 confers resistance to trametinib in colorectal cancer cells.Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors.Hormone-induced DNA damage response and repair mediated by cyclin D1 in breast and prostate cancer.Novel DNA targeted therapies for head and neck cancers: clinical potential and biomarkers.Emerging treatment options for ovarian cancer: focus on rucaparib.Current status of poly(ADP-ribose) polymerase inhibitors and future directions.Combining DNA damaging therapeutics with immunotherapy: more haste, less speed.HMG-CoA reductase inhibition delays DNA repair and promotes senescence after tumor irradiation.Directing the use of DDR kinase inhibitors in cancer treatment.Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program.Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents.Double duty: ZMYND8 in the DNA damage response and cancer.Genetic modifiers of Mendelian disease: Huntington's disease and the trinucleotide repeat disorders.Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors.Evaluating In Vitro DNA Damage Using Comet Assay.The central role of DNA damage and repair in CAG repeat diseases.Approaches for Identifying Novel Targets in Precision Medicine: Lessons from DNA Repair.Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas.Metal-based NanoEnhancers for Future Radiotherapy: Radiosensitizing and Synergistic Effects on Tumor Cells.Targeting DNA damage repair in small cell lung cancer and the biomarker landscape.Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.Precision Medicine in Head and Neck Cancer: Myth or Reality?Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancer.Polymorphisms of the Ras-Association Domain Family 1 Isoform A (RASSF1A) Gene are Associated with Ovarian Cancer, and with the Prognostic Factors of Grade and Stage, in Women in Southern China.Advances in therapeutic targeting of the DNA damage response in cancer.Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies.Melatonin Sensitizes Hepatocellular Carcinoma Cells to Chemotherapy Through Long Non-Coding RNA RAD51-AS1-Mediated Suppression of DNA Repair
P2860
Q37675896-BEFD2CCB-BF63-4494-A2F1-C99BB00E6084Q38644204-5122C918-7450-4999-BF3B-9943AFD7EEC2Q38707814-6A02D60D-92CA-4933-B984-0FD30A5842C3Q39233197-7847EECE-45B8-41F9-AB02-C49FD3D435B5Q39324161-9AD25A46-5836-46EA-86E7-53E692E9CA33Q39384263-08FCA4FD-1B72-40E1-BDFD-581796F9DB43Q39393235-B67D40A9-F773-497E-8E63-A6C907C6D10DQ39434457-9505B34A-EBEB-42EB-A10C-AF6D542D6038Q40114381-BE6BF164-2E39-455E-B690-2C351EBE904BQ41552673-227E5E32-B7D7-45E4-B9B5-93914FDDE72DQ44420270-22E6D2D5-2F09-4517-84DB-343DF7055C7CQ45790068-9D1227A6-C487-406C-9E29-8069820F127CQ47107471-ECC40813-286F-4A0F-B70B-A34C79690FECQ47155297-174A55AB-5551-48BA-AB0C-106BFB2EDE6AQ47621538-C45D192E-1366-4E2C-BA6A-124D5584E04DQ47655012-305DC503-1CDE-44E7-8623-F721AD5ADB26Q47687840-7BD192A3-966C-4634-B003-156206E1EA24Q47786231-CA34190B-7E35-402A-A5CF-B4F1019DE5F8Q47808353-7DFF5C20-63BE-4137-A30A-12096697B391Q49377046-28B70DB3-F1A6-41B6-A53B-388A19BB1F76Q49608512-F04CAC9C-7EBC-44A0-9F38-FEFAD9638A7DQ49679908-73016573-F0EA-4ADE-B62C-8B64DFE4588CQ50061350-42FC5AA6-FE4F-444C-BB67-DB4D95876784Q50118950-CD442B84-6D6F-4454-B117-8A492347A93AQ51800946-0266DFA9-72E9-4528-93F7-BB1356CA8E0AQ52607320-55BC20A0-A802-46FD-A05B-EB45B47B401DQ52647643-0355AB2F-5E64-4C34-AB94-1FCA3EEC89C8Q52657032-D660596E-EECE-43CB-B46E-073300F0C8C3Q53730678-76B8FF34-C31A-4DC1-A0A1-3ACB5B9D45D5Q55012383-C93020D2-081C-43AF-B9D8-D69B1F38F140Q55109090-C101F8BC-6FB4-4D87-BCC7-832DE3DEC235Q55114053-050A8950-C006-43D1-BD53-4D41CB0E2122Q55306606-CB3CA8FF-EDEA-4E33-A7B3-318D72A9D6DCQ55710290-CC83E62B-E67D-4031-802D-D44E0604B850Q58753461-887F440A-8AE5-417A-A04C-78A5BD54BB64
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 December 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.
@en
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.
@nl
type
label
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.
@en
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.
@nl
prefLabel
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.
@en
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.
@nl
P2860
P1433
P1476
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
@en
P2093
Jessica S Brown
Timothy A Yap
P2860
P356
10.1158/2159-8290.CD-16-0860
P577
2016-12-21T00:00:00Z